Steris (NYSE:STE) reported quarterly earnings of $1.90 per share which missed the analyst consensus estimate of $1.91 by 0.52 percent. This is a 7.95 percent increase over earnings of $1.76 per share from the same period last year.
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering